PH12021550750A1 - Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications - Google Patents

Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications

Info

Publication number
PH12021550750A1
PH12021550750A1 PH12021550750A PH12021550750A PH12021550750A1 PH 12021550750 A1 PH12021550750 A1 PH 12021550750A1 PH 12021550750 A PH12021550750 A PH 12021550750A PH 12021550750 A PH12021550750 A PH 12021550750A PH 12021550750 A1 PH12021550750 A1 PH 12021550750A1
Authority
PH
Philippines
Prior art keywords
binding protein
anthracyclines
immune
toxin conjugates
oncological applications
Prior art date
Application number
PH12021550750A
Other languages
English (en)
Inventor
Ulf Grawunder
Roger Beerli
Lorenz Waldmeier
Francesca Pretto
Original Assignee
Nbe Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nbe Therapeutics Ag filed Critical Nbe Therapeutics Ag
Publication of PH12021550750A1 publication Critical patent/PH12021550750A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PH12021550750A 2018-10-11 2021-04-05 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications PH12021550750A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18199879.0A EP3636284A1 (en) 2018-10-11 2018-10-11 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
PCT/EP2019/077644 WO2020074724A1 (en) 2018-10-11 2019-10-11 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications

Publications (1)

Publication Number Publication Date
PH12021550750A1 true PH12021550750A1 (en) 2022-02-21

Family

ID=63833918

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550750A PH12021550750A1 (en) 2018-10-11 2021-04-05 Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications

Country Status (12)

Country Link
US (1) US20210379194A1 (cg-RX-API-DMAC7.html)
EP (2) EP3636284A1 (cg-RX-API-DMAC7.html)
JP (1) JP7607556B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210075085A (cg-RX-API-DMAC7.html)
CN (1) CN112805037A (cg-RX-API-DMAC7.html)
AU (1) AU2019358518A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006269A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112848A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190653A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021003136A (cg-RX-API-DMAC7.html)
PH (1) PH12021550750A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020074724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ror1結合タンパク質を発現する細胞を培養する方法
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
BR122020025870B1 (pt) 2014-12-23 2024-01-09 Nbe-Therapeutics Ag Método para a produção de um conjugado de proteína de ligaçãofármaco
US20180028682A1 (en) 2015-02-09 2018-02-01 Nbe Therapeutics Ag Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
CA3001941A1 (en) 2015-10-30 2017-05-04 Nbe-Therapeutics Ag Anti-ror1 antibodies
US20190112385A1 (en) 2015-10-30 2019-04-18 Nbe-Therapeutics Ag Anti-mesothelin antibodies
MX2018008926A (es) * 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
CN109311982A (zh) * 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
PL3964529T3 (pl) * 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
SG11201901624RA (en) * 2016-09-07 2019-03-28 Univ Canberra Lysine specific histone demethylase-1 inhibitors and uses therefor
WO2018103739A1 (zh) * 2016-12-09 2018-06-14 凯惠科技发展(上海)有限公司 抗体药物偶联物、制备方法、中间体、药物组合物及应用
JP7359700B2 (ja) * 2017-06-20 2023-10-11 ソレント・セラピューティクス・インコーポレイテッド Cd38抗体薬物コンジュゲート
US20210139579A1 (en) * 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
KR20230008269A (ko) * 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules

Also Published As

Publication number Publication date
WO2020074724A1 (en) 2020-04-16
CN112805037A (zh) 2021-05-14
EP3636284A1 (en) 2020-04-15
BR112021006269A2 (pt) 2021-08-10
JP7607556B2 (ja) 2024-12-27
JP2022512672A (ja) 2022-02-07
CA3112848A1 (en) 2020-04-16
KR20210075085A (ko) 2021-06-22
AU2019358518A1 (en) 2021-04-08
EA202190653A1 (ru) 2021-05-26
US20210379194A1 (en) 2021-12-09
MX2021003136A (es) 2021-08-19
EP3863681A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
IL284393A (en) The claudin18.2 binding groups and their uses
EP4081551A4 (en) CLAUDIN18.2 BINDING FRACTIONS AND THEIR USES
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
NZ795274A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
IL286862A (en) Bicycle toxin conjugates and uses thereof
MY206244A (en) Anti-muc1 antibody-drug conjugate
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
MX2025011666A (es) Composiciones anti-cd112r y metodos
IL279133A (en) Binder-drug conjugates activated in the microenvironment and their related uses
MX2021003136A (es) Conjugados de proteinas de union a toxinas que comprenden antraciclinas, y uso de los mismos en aplicaciones inmunooncologicas.
WO2019178269A3 (en) Antibodies that bind cd39 and uses thereof
IL278877A (en) Amino-pyrazinecarboxamide compounds, conjugates and their uses
EP4302782A3 (en) Napi2b-targeted antibody-drug conjugates and methods of use thereof
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2025009320A (es) Anticuerpos anti-cd19 novedosos
IL272931A (en) Peptide conjugates, conjugation process and their uses
EP3843736A4 (en) ISOQUINOLINE STEROID CONJUGATES AND USES THEREOF
EP4275516A3 (en) Steviol glycoside compositions
SA519401424B1 (ar) Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها
EP3959242A4 (en) ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
HK40058411A (en) Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
HK40055071A (en) Claudin18.2 binding moieties and uses thereof
HK40021772A (en) Peptide conjugates, conjugation process, and uses thereof
WO2021059256A9 (en) The numbers, letters and other signs that see up to 360 degree arc.
HK40040382A (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto